Search
Expert opinions for COVID-19 vaccination in patients with hematologic cancer
Ronja Brockhoff, Hamdi Akan, Rafael Duarte, Martin Hönigl, Nikolay Klimko, Sibylle C. Mellinghoff, Livio Pagano, Antonio Pagliuca, Paul Verweij, Oliver A.
Read moreRegistration
Register for the on-demand recordings
Individual registration
The virtual registration includes:
On-demand access to the recordings of the scientific and educational sessions of the meeting that took place 10-12 November, 2022.
T2EVOLVE: breakthrough alliance boosting Europe to the forefront of cancer immunotherapy
This press release is originally found here: http://prn. to/2YF7Js3
THE HAGUE, Netherlands, Feb. 3, 2021 /PRNewswire/ -- T2EVOLVE is a new breakthrough alliance of academic and industry leaders in cancer immunotherapy under the European Union's Innovative Medicines Initiative (IMI).
I would like to be an EHA Member
Our members come from all corners of the world – from a University Hospitals in India to research companies in Germany.
Read morePolicy & advocacy
At the core of EHA’s advocacy efforts are four priority themes. For each of these themes, the main messages and recommendations directed at EU institutions and other stakeholders have been written down in a Position Paper.
Read moreEHA Bilateral Collaborative Grant
The call for applications will close on October 15, 2024, at 15:00 (CEST).
Read moreChallenging the safety of conformity: Better poster design to disseminate scientific knowledge fast
“Congratulations – your abstract was accepted for the upcoming EHA congress”.
Read moreExpert opinions for COVID-19 vaccination in patients with non-malignant hematologic diseases
Carlo Dufour, Helen Papadaki, Alan Warren, Colm Bradley, Cristina Mecucci, Jan Palmblad, Cornelia Zeidler, Francesca Fioredda, Sam Salek, Brigitte Schlegelberger and Daniela Guardo, on behalf of the EHA SWG on Granulocytes and Constitutional Marrow Failure Disorders; Carlo L.
Read more